Table 2.
Guideline concordant treatment, n (Row %) | Univariable OR (95% CI) | P | Multivariable OR (95% CI)a | P | ||
---|---|---|---|---|---|---|
No (n = 17,089) | Yes (n = 13,337) | |||||
Race/ethnicity | 0.46 | 0.59 | ||||
NHW | 11,937 (56.4%) | 9240 (43.6%) | 1.00 | 1.00 | ||
NHB | 3714 (55.8%) | 2943 (44.2%) | 1.02 (0.97–1.08) | 1.01 (0.95–1.07) | ||
Hispanic | 951 (56.3%) | 738 (43.7%) | 1.00 (0.91–1.11) | 1.01 (0.91–1.12) | ||
AS/PI | 487 (53.9%) | 416 (46.1%) | 1.10 (0.97–1.26) | 1.10 (0.96–1.26) | ||
Age | <0.0001 | <0.0001 | ||||
18–44 | 261 (60.0%) | 174 (40.0%) | 1.00 | 1.00 | ||
45–54 | 1037 (56.9%) | 786 (43.1%) | 1.14 (0.92–1.41) | 1.30 (0.98–1.73) | ||
55–64 | 5022 (55.3%) | 4065 (44.7%) | 1.21 (1.00–1.48) | 1.37 (1.04–1.81) | ||
65–74 | 6153 (54.5%) | 5143 (45.5%) | 1.25 (1.03–1.52) | 1.40 (1.06–1.84) | ||
≥75 | 4616 (59.3%) | 3169 (40.7%) | 1.03 (0.85–1.25) | 1.19 (0.90–1.57) | ||
Stage | <0.0001 | <0.0001 | ||||
I | 80 (47.9%) | 87 (52.1%) | 1.00 | 1.00 | ||
IA | 3016 (39.0%) | 4710 (61.0%) | 1.44 (1.06–1.95) | 1.53 (1.12–2.08) | ||
IB | 2824 (67.5%) | 1359 (32.5%) | 0.44 (0.32–0.60) | 0.46 (0.33–0.62) | ||
IC | 547 (53.8%) | 470 (46.2%) | 0.79 (0.57–1.10) | 0.82 (0.59–1.14) | ||
II | 1087 (74.1%) | 381 (26.0%) | 0.32 (0.23–0.45) | 0.33 (0.24–0.46) | ||
IIA | 274 (61.6%) | 171 (38.4%) | 0.57 (0.40–0.82) | 0.61 (0.43–0.88) | ||
IIB | 443 (56.2%) | 346 (43.9%) | 0.72 (0.51–1.00) | 0.76 (0.54–1.06) | ||
III | 117 (64.6%) | 64 (35.4%) | 0.50 (0.33–0.77) | 0.53 (0.35–0.82) | ||
IIIA | 1422 (57.0%) | 1075 (43.1%) | 0.70 (0.51–0.95) | 0.73 (0.53–1.00) | ||
IIIB | 409 (67.7%) | 195 (32.3%) | 0.44 (0.31–0.62) | 0.45 (0.31–0.63) | ||
IIIC | 3236 (59.1%) | 2244 (41.0%) | 0.64 (0.47–0.87) | 0.67 (0.49–0.91) | ||
IV | 348 (67.8%) | 165 (32.2%) | 0.44 (0.31–0.62) | 0.47 (0.33–0.67) | ||
IVA | 365 (64.2%) | 204 (35.9%) | 0.51 (0.36–0.73) | 0.54 (0.38–0.76) | ||
IVB | 2921 (61.0%) | 1866 (39.0%) | 0.59 (0.43–0.80) | 0.62 (0.45–0.84) | ||
Histology | <0.0001 | <0.0001 | ||||
Carcinosarcoma | 6030 (53.8%) | 5177 (46.2%) | 1.00 | 1.00 | ||
Clear cell | 1971 (57.6%) | 1451 (42.4%) | 0.86 (0.79–0.93) | 0.78 (0.72–0.84) | ||
Serous | 9088 (57.5%) | 6709 (42.5%) | 0.86 (0.82–0.90) | 0.78 (0.74–0.82) | ||
Charlson comorbidity score | 0.72 | |||||
0 | 12,617 (56.0%) | 9901 (44.0%) | 1.00 | - | ||
1 | 3639 (56.8%) | 2772 (43.2%) | 0.97 (0.92–1.03) | - | ||
2 | 668 (55.8%) | 529 (44.2%) | 1.01 (0.90–1.13) | - | ||
≥3 | 165 (55.0%) | 135 (45.0%) | 1.04 (0.83–1.31) | - | ||
Hospital type | 0.04 | 0.02 | ||||
Community cancer program | 679 (55.7%) | 541 (44.3%) | 1.00 | 1.00 | ||
Comprehensive community cancer program | 6329 (57.3%) | 4717 (42.7%) | 0.94 (0.83–1.05) | 0.90 (0.80–1.02) | ||
Academic/research program | 7877 (55.4%) | 6353 (44.7%) | 1.01 (0.90–1.14) | 0.97 (0.86–1.10) | ||
Integrated network cancer program | 2096 (56.2%) | 1637 (43.9%) | 0.98 (0.86–1.12) | 0.93 (0.81–1.06) | ||
Other/unknown | 108 (54.8%) | 89 (45.2%) | 1.03 (0.76–1.40) | 1.30 (0.86–1.96) | ||
Hospital location | <0.0001 | |||||
Northeast | 4244 (57.6%) | 3131 (42.5%) | 1.00 | |||
South | 5976 (55.4%) | 4820 (44.7%) | 1.09 (1.03–1.16) | - | ||
Midwest | 3995 (55.0%) | 3273 (45.0%) | 1.11 (1.04–1.19) | - | ||
Mountain | 657 (62.2%) | 399 (37.8%) | 0.82 (0.72–0.94) | - | ||
Pacific | 2109 (56.5%) | 1625 (43.5%) | 1.04 (0.97–1.13) | - | ||
Unknown | 108 (54.8%) | 89 (45.2%) | 1.12 (0.84–1.48) | - | ||
Urban/rural | 0.99 | |||||
Metro | 14,035 (56.2%) | 10,962 (43.9%) | 1.00 | - | ||
Urban | 2203 (56.1%) | 1721 (43.9%) | 1.00 (0.94–1.07) | - | ||
Rural | 311 (56.9%) | 236 (43.1%) | 0.97 (0.82–1.15) | - | ||
Unknown | 540 (56.4%) | 418 (43.6%) | 0.99 (0.87–1.13) | - | ||
Incomeb | 0.20 | |||||
≤$38,000 | 3357 (56.2%) | 2613 (43.8%) | 1.00 | - | ||
$38,000-$47,999 | 3723 (56.2%) | 2908 (43.9%) | 1.00 (0.94–1.08) | - | ||
$48,000-$62,999 | 4337 (55.5%) | 3484 (44.6%) | 1.03 (0.96–1.10) | - | ||
≥$63,000 | 5450 (56.5%) | 4192 (43.5%) | 0.99 (0.93–1.06) | - | ||
Unknown | 222 (61.3%) | 140 (38.7%) | 0.81 (0.65–1.01) | - | ||
Education (% without high school diploma)c | 0.27 | |||||
≥21% | 3268 (57.0%) | 2467 (43.0%) | 1.00 | - | ||
13%−20.9% | 4414 (55.9%) | 3483 (44.1%) | 1.05 (0.98–1.12) | - | ||
7%−12.9% | 5257 (55.9%) | 4155 (44.2%) | 1.05 (0.98–1.12) | - | ||
<7% | 3938 (56.0%) | 3095 (44.0%) | 1.04 (0.97–1.18) | - | ||
Unknown | 212 (60.7%) | 137 (39.3%) | 0.86 (0.69–1.07) | - | ||
Insurance | <0.0001 | <0.0001 | ||||
None | 530 (55.6%) | 424 (44.4%) | 1.00 | 1.00 | ||
Private | 5842 (55.7%) | 4655 (44.4%) | 1.00 (0.87–1.14) | 0.99 (0.86–1.13) | ||
Medicaid | 862 (58.2%) | 618 (41.8%) | 0.90 (0.76–1.06) | 0.93 (0.79–1.10) | ||
Medicare | 9450 (56.1%) | 7392 (43.9%) | 0.98 (0.86–1.12) | 1.04 (0.90–1.21) | ||
Other government | 114 (52.5%) | 103 (47.5%) | 1.13 (0.84–1.52) | 1.11 (0.82–1.51) | ||
Unknown | 291 (66.7%) | 145 (33.3%) | 0.62 (0.49–0.79) | 0.65 (0.51–0.83) |
Hospital location not included in adjusted model due to collinearity with facility type.
Income: quartiles based on equally proportioned income ranges among all U.S. zip codes.
Education: quartiles based on proportion of adults in the patient’s zip code who did not graduate from high school.